{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:58:54Z","timestamp":1774364334536,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.ejim.2010.08.004","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T06:31:48Z","timestamp":1284705108000},"page":"484-489","source":"Crossref","is-referenced-by-count":12,"title":["Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: Facts or fancies?"],"prefix":"10.1016","volume":"21","author":[{"given":"Maddalena","family":"Lettino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2010.08.004_bb0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejim.2010.08.004_bb0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.08.004_bb0015","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","article-title":"Combination antithrombotic therapies","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.08.004_bb0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent Interventional Cooperative Study","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.08.004_bb0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.107.188208","volume":"117","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.08.004_bb0030","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2010.08.004_bb0035","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1053\/euhj.2002.3385","article-title":"Management of acute coronary syndromes in patients presenting without persistent ST-elevation","volume":"23","author":"Bertrand","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2010.08.004_bb0040","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2010.08.004_bb0045","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial","volume":"366","author":"COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.08.004_bb0050","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of Acute Myocardial Infarction in patients presenting with persistent ST-segment elevation","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2010.08.004_bb0055","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1021\/ja049607w","article-title":"Chemistry of covalent inhibition of the gastric (H+\/K+)-ATPase by proton pump inhibitors","volume":"126","author":"Shin","year":"2004","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ejim.2010.08.004_bb0060","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on humans Cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.ejim.2010.08.004_bb0065","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-008-0538-y","article-title":"Proton pump inhibitors: an update of their clinical use and pharmacokinetics","volume":"64","author":"Shi","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejim.2010.08.004_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200847010-00001","article-title":"Proton pump inhibitors. Do differences in pharmacokinetics translate into differences in clinical outcomes?","volume":"47","author":"Fock","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejim.2010.08.004_bb0075","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am J Gastroenetrol"},{"key":"10.1016\/j.ejim.2010.08.004_bb0080","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","article-title":"Systemic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials","volume":"119","author":"McQuaid","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2010.08.004_bb0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/030079907X162656","article-title":"Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment","volume":"23","author":"Lanas","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2010.08.004_bb0090","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1073\/pnas.111150798","article-title":"Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release","volume":"98","author":"Ma","year":"2001","journal-title":"Procl Nat Acad Sci U S A."},{"key":"10.1016\/j.ejim.2010.08.004_bb0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MCG.0b013e31802e63ff","article-title":"Upper gastrointestinal bleeding in patients with acute coronary syndromes. Clinical predictors and prophylactic role of proton pump inhibitors","volume":"42","author":"Barada","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ejim.2010.08.004_bb0100","unstructured":"Bhatt DL. COGENT: a prospective, plecebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, 24 September 2009. San Francisco, CA."},{"key":"10.1016\/j.ejim.2010.08.004_bb0105","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology task force on clinical expert consensus documents","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.08.004_bb0110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin","volume":"51","author":"Gilard","year":"2008","journal-title":"JACC"},{"key":"10.1016\/j.ejim.2010.08.004_bb0115","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","article-title":"Comparison of omeprazole and pantoprazole influence on high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective, randomized study","volume":"54","author":"Cuisset","year":"2009","journal-title":"JACC"},{"key":"10.1016\/j.ejim.2010.08.004_bb0120","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.ahj.2008.09.017","article-title":"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel","volume":"157","author":"Siller-Matula","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2010.08.004_bb0125","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","article-title":"Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2010.08.004_bb0130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejim.2010.08.004_bb0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.ejim.2010.08.004_bb0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejim.2010.08.004_bb0145","first-page":"32","article-title":"Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel","volume":"87","author":"Kwok","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2010.08.004_bb0150","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration A systematic meta-analysis.","volume":"56","author":"Hulot","year":"2010","journal-title":"JACC"},{"key":"10.1016\/j.ejim.2010.08.004_bb0155","unstructured":"U.S. Food and Drug Administration. Public Health Advisory: updated safety information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec or Prilosec OTC). 17 November 2009. http\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/ucm190825.htm"},{"key":"10.1016\/j.ejim.2010.08.004_bb0160","unstructured":"European Medicine Agency. Public statement of interaction between clopidogrel and proton pump inhibitors. 17 March 2010. http\/\/www.emea.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/03\/news_detail_001008.jsp&mid.=WC0b01ac058004d5"},{"key":"10.1016\/j.ejim.2010.08.004_bb0165","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMe0906549","article-title":"Ticagrelor\u2014is there need for a new player in the antiplatelet-therapy field?","volume":"361","author":"Sh\u00f6mig","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.08.004_bb0170","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ejim.2009.09.005","article-title":"New antiplatelet agents: why they are needed","volume":"20","author":"Franchini","year":"2009","journal-title":"Eur J Int Med"},{"issue":"8","key":"10.1016\/j.ejim.2010.08.004_bb0175","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archinternmed.2010.34","article-title":"Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor","volume":"107","author":"Stockl","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2010.08.004_bb0180","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/CIRCULATIONAHA.109.873497","article-title":"Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome","volume":"120","author":"Rassen","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.08.004_bb0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-152-6-201003160-00003","article-title":"Outcomes with concurrent use of clopidogrel and proton-pump inhibitors","volume":"152","author":"Ray","year":"2010","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510001652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510001652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T17:27:22Z","timestamp":1559669242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620510001652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0953620510001652"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2010.08.004","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}